Vera Therapeutics (VERA) Return on Capital Employed (2021 - 2026)
Vera Therapeutics' (VERA) quarterly Return on Capital Employed came in at 60.56% in Q1 2026, down 2893.0% YoY from 2.17% in Q1 2025, and down 9.94% on a QoQ basis from 55.09% in Q4 2025.
Vera Therapeutics (VERA) Return on Capital Employed (2021 - 2026) Analysis & Trends
Vera Therapeutics (VERA) has 6 years of Return on Capital Employed data on file, last reported at 60.56% in Q1 2026.
- Quarterly Return on Capital Employed fell 2893.0% year-over-year to 60.56% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 60.56% (down 2893.0% YoY) and the FY2025 annual result came in at 49.16%, down 632.0% from the prior year.
- Return on Capital Employed retreated to 60.56% in Q1 2026, from 55.09% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 30.07% in Q2 2024 to a low of 85.92% in Q4 2022.
- A 5-year average of 51.98% and a median of 53.38% in 2025 frame the typical range for Return on Capital Employed.
- The widest YoY moves for Return on Capital Employed: up 6547 bps in 2022, down 4279 bps in 2022.
- Tracing VERA's Return on Capital Employed over 5 years: stood at 85.92% in 2022, then rose by 23 bps to 66.55% in 2023, then jumped by 48 bps to 34.34% in 2024, then sank by 60 bps to 55.09% in 2025, then retreated by 10 bps to 60.56% in 2026.
- The last three Return on Capital Employed figures came in at 60.56% (Q1 2026), 55.09% (Q4 2025), and 53.38% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Vera Therapeutics | 2.28 Bn | 2.28 Bn | - | -78.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -78.59% |
| Mar 31, 2026 | -60.56% |
| Dec 31, 2025 | -55.09% |
| Sep 30, 2025 | -53.38% |
| Jun 30, 2025 | -42.09% |
| Mar 31, 2025 | -31.63% |
| Dec 31, 2024 | -34.34% |
| Sep 30, 2024 | -40.76% |
| Jun 30, 2024 | -30.07% |
| Mar 31, 2024 | -36.01% |
| Dec 31, 2023 | -66.55% |
| Sep 30, 2023 | -67.53% |
| Jun 30, 2023 | -63.83% |
| Mar 31, 2023 | -71.53% |
| Dec 31, 2022 | -85.92% |
| Sep 30, 2022 | -59.53% |
| Jun 30, 2022 | -40.05% |
| Mar 31, 2022 | -44.74% |
| Dec 31, 2021 | -43.13% |
| Sep 30, 2021 | -66.81% |